By proceeding, you agree to our Terms of Use and Privacy Policy.
Opthea is a clinical stage biopharmaceutical company committed to developing innovative therapies to help improve visual function in patients suffering with retinal diseases. Our first in class novel therapeutic called OPT-302, is a VEGF-C/D ‘trap’, to be used in combination with existing standard of care anti-VEGF-A therapies to improve vision in patients, many of whom respond sub-optimally or become refractory to existing treatments.
27-27 July 2023
Welcome to OIS Retina 2023, the leading gathering of clinical, corporate, and capital leaders dedicated to advancing novel technologies and addressing the most significant unmet medical needs in the field of retina. This highly anticipated event brin
Event Ended
USA
Paid
Seattle